See other companies on Welcome to the Jungle
Quell Therapeutics
Cell therapy company
- 101-200 employees
- Healthcare
- B2B
- Education
- Biology
- London, UK
Jump to section
Company mission
To develop engineered T regulatory (Treg) cell therapies.
Our take
T-regulator (Treg) cells play a crucial role in modulating immune responses and maintaining immune tolerance. However, in certain diseases, such as autoimmune disorders, the balance of the immune system is disrupted. Quell Therapeutics is a biotechnology company that aims to address these conditions by engineering Treg cells to enhance their therapeutic potential and direct their immune-suppressive properties towards specific disease targets.
Quell Therapeutics has been recognised as a leader in the field of Treg cell therapies. Building upon its expertise, the company recently partnered with Cellistic, an iPSC-focused cell therapy platform. This collaboration allows Quell Therapeutics to expand its pipeline and take advantage of the capabilities of Cellistic's platform in order to further enhance the development of its Treg cell therapies.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Holidays: 25 days per year
- Flexible working environment
- Life Assurance: 4 x base salary
- Group Personal Pension: Auto enrolled at 6% employer contribution, 3% employee contribution
- Private Medical Insurance for your whole family
- Annual Bonus
Company values
- Collaborative
- Innovative
- Respectful
- Accountable
- Integrity
Funding (last 2 of 3 rounds)
Nov 2021
$156m
SERIES B
Feb 2021
$35.7m
SERIES A
Total funding: $236.2m
Leadership
Marc Martinez-Llordella
(Co-Founder)Received a PhD in Biomedicine from the University of Barcelona. Previously worked as a Lecturer at the King's College London.